Stock Track | Moderna Soars 5.01% Intraday on Ebola Vaccine Trial Launch, Earnings Anticipation

Stock Track

Jul 31

Shares of Moderna, Inc. (MRNA) soared 5.01% during intraday trading on Thursday, driven by the company's announcement of a new clinical trial for an Ebola vaccine and optimism ahead of its upcoming earnings report.

The biotech firm disclosed the launch of a Phase 1 study for its mRNA-1469 vaccine candidate, which aims to prevent Ebola virus infection. This move to expand its mRNA pipeline beyond respiratory diseases signals potential new revenue streams and reinforces Moderna's platform versatility, boosting investor confidence.

Additionally, traders are positioning ahead of Moderna's earnings release scheduled for Friday, with some market sentiment leaning toward a positive surprise, adding further upward momentum to the stock.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1199189721"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1199189721\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1199189721?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-31 02:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1199189721","market":"nz","top_or_hot":-1,"title":"Stock Track | Moderna Soars 5.01% Intraday on Ebola Vaccine Trial Launch, Earnings Anticipation","media":"Stock Track","content":"<p>Shares of Moderna, Inc. (MRNA) soared 5.01% during intraday trading on Thursday, driven by the company's announcement of a new clinical trial for an Ebola vaccine and optimism ahead of its upcoming earnings report.</p><p>The biotech firm disclosed the launch of a Phase 1 study for its mRNA-1469 vaccine candidate, which aims to prevent Ebola virus infection. This move to expand its mRNA pipeline beyond respiratory diseases signals potential new revenue streams and reinforces Moderna's platform versatility, boosting investor confidence.</p><p>Additionally, traders are positioning ahead of Moderna's earnings release scheduled for Friday, with some market sentiment leaning toward a positive surprise, adding further upward momentum to the stock.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Moderna Soars 5.01% Intraday on Ebola Vaccine Trial Launch, Earnings Anticipation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Moderna Soars 5.01% Intraday on Ebola Vaccine Trial Launch, Earnings Anticipation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-07-31 02:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Moderna, Inc. (MRNA) soared 5.01% during intraday trading on Thursday, driven by the company's announcement of a new clinical trial for an Ebola vaccine and optimism ahead of its upcoming earnings report.</p><p>The biotech firm disclosed the launch of a Phase 1 study for its mRNA-1469 vaccine candidate, which aims to prevent Ebola virus infection. This move to expand its mRNA pipeline beyond respiratory diseases signals potential new revenue streams and reinforces Moderna's platform versatility, boosting investor confidence.</p><p>Additionally, traders are positioning ahead of Moderna's earnings release scheduled for Friday, with some market sentiment leaning toward a positive surprise, adding further upward momentum to the stock.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRNA","symbol_name":"Moderna, Inc.","start_time":0,"source_url":"","article_id":"1199189721","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1199189721","pubTimestamp":1785437464,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Moderna, Inc. (MRNA) soared 5.01% during intraday trading on Thursday, driven by the company's announcement of a new clinical trial for an Ebola vaccine and optimism ahead of its upcoming...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRNA":"Moderna, Inc."},"translate_title":"股票跟踪 | 埃博拉疫苗试验启动，Moderna 盘中飙升 5.01%，盈利预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRNA":1},"content_text":"Shares of Moderna, Inc. (MRNA) soared 5.01% during intraday trading on Thursday, driven by the company's announcement of a new clinical trial for an Ebola vaccine and optimism ahead of its upcoming earnings report.The biotech firm disclosed the launch of a Phase 1 study for its mRNA-1469 vaccine candidate, which aims to prevent Ebola virus infection. This move to expand its mRNA pipeline beyond respiratory diseases signals potential new revenue streams and reinforces Moderna's platform versatility, boosting investor confidence.Additionally, traders are positioning ahead of Moderna's earnings release scheduled for Friday, with some market sentiment leaning toward a positive surprise, adding further upward momentum to the stock.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}